Georgiamune
Regulating signaling pathways to restore immune balance and fight cancer and autoimmune diseases, utilizing first-in-class assets with a robust pipeline of immunomodulators.
Launch date
Employees
Market cap
-
Enterprise valuation
€273—409m (Dealroom.co estimates Aug 2023.)
Gaithersburg Maryland (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
* | $75.0m | Series A | |
Total Funding | €68.2m |